Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity

Immunology

Volumn 146, Issue 3, 2015, Pages 369-378

  Xiong, Peng ^a   Sang, Hai Wei ^a   Zhu, Min ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

DNAM 1; DNAM 1 ligands; Infections; Natural killer cells; Tumours

Indexed keywords

CD155 ANTIGEN; DNAX ACCESSORY MOLECULE 1 PROTEIN; MEMBRANE PROTEIN; NECTIN 2; UNCLASSIFIED DRUG; CD226 ANTIGEN; LIGAND; POLIOVIRUS RECEPTOR; T LYMPHOCYTE ANTIGEN; VIRUS RECEPTOR;

3' UNTRANSLATED REGION; ARTICLE; CANCER CONTROL; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CELLULAR STRESS RESPONSE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA DAMAGE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; INFECTION CONTROL; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; IMMUNOLOGY; INFECTION; NEOPLASM; TUMOR ESCAPE;

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; AUTOIMMUNE DISEASES; HUMANS; INFECTION; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; NEOPLASMS; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 84943641319     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12516     Document Type: Article

References (99)

1. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975; 16:216-29.
2. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5:112-17.
3. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol 2003; 3:413-25.
4. Watzl C, Urlaub D, Fasbender F, Claus M. Natural killer cell regulation - beyond the receptors. F1000Prime Rep 2014; 6:87.
5. Watzl C. How to trigger a killer: modulation of natural killer cell reactivity on many levels. Adv Immunol 2014; 124:137-70.
6. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31:227-58.
7. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9.
8. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004; 23:255-9.
9. Bellora F, Castriconi R, Dondero A, Carrega P, Mantovani A, Ferlazzo G, Moretta A, Bottino C. Human NK cells and NK receptors. Immunol Lett 2014; 161:168-73.
10. Burns GF, Triglia T, Werkmeister JA, Begley CG, Boyd AW. TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors. J Exp Med 1985; 161:1063-78.
11. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996; 4:573-81.
12. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198:557-67.
13. de Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol 2014; 92:237-44.
14. Hou S, Ge K, Zheng X, Wei H, Sun R, Tian Z. CD226 protein is involved in immune synapse formation and triggers Natural Killer (NK) cell activation via its first extracellular domain. J Biol Chem 2014; 289:6969-77.
15. Nabekura T, Kanaya M, Shibuya A, Fu G, Gascoigne NRJ, Lanier LL. Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity 2014; 40:225-34.
16. Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014; 15:431-8.
17. Enqvist M, Ask EH, Forslund E, Carlsten M, Abrahamsen G, Beziat V et al. Coordinated expression of DNAM-1 and LFA-1 in educated NK cells. J Immunol 2015; 194:4518-27.
18. Martinet L, Ferrari De Andrade L, Guillerey C, Lee JS, Liu J, Souza-Fonseca-Guimaraes F et al. DNAM-1 expression marks an alternative program of NK Cell maturation. Cell Rep 2015; 11:85-97.
19. Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 2015; 15:243-54.
20. Liu J, Qian X, Chen Z, Xu X, Gao F, Zhang S et al. Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226. J Immunol 2012; 188:5511-20.
21. Beaulieu AM, Bezman NA, Lee JE, Matloubian M, Sun JC, Lanier LL. MicroRNA function in NK-cell biology. Immunol Rev 2013; 253:40-52.
22. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, Cook GP. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS ONE 2011; 6:e22842.
23. Hromadnikova I, Pirkova P, Sedlackova L. Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors. Mediators Inflamm 2013; 2013:405295.
24. Penafuerte C, Bautista-Lopez N, Boulassel MR, Routy JP, Galipeau J. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. Cancer Res 2009; 69:9020-8.
25. Moustaki A, Argyropoulos KV, Baxevanis CN, Papamichail M, Perez SA. Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function. Cancer Immunol Immunother 2011; 60:1683-95.
26. Cremer I, Fridman WH, Sautes-Fridman C. Tumor microenvironment in NSCLC suppresses NK cells function. Oncoimmunology 2012; 1:244-6.
27. Wang L, Zhang W, Wu DA, Chen C, Xu QZ, Zhao B et al. Molecular cloning, characterization and three-dimensional modeling of porcine nectin-2/CD112. Vet Immunol Immunopathol 2009; 132:257-63.
28. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A et al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 2006; 107:2030-6.
29. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, Bottino C, Moretta A. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004; 64:9180-4.
30. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413-41.
31. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9:568-80.
32. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113:3503-11.
33. Soriani A, Fionda C, Ricci B, Iannitto ML, Cippitelli M, Santoni A. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. Oncoimmunology 2013; 2:e26663.
34. Croxford JL, Tang MLF, Pan MF, Huang CW, Kamran N, Phua CML et al. ATM-dependent spontaneous regression of early E mu-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood 2013; 121:2512-21.
35. Vassena L, Giuliani E, Matusali G, Cohen EA, Doria M. The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the AIR-mediated DNA damage response pathway. J Gen Virol 2013; 94:2664-9.
36. Fionda C, Abruzzese MP, Zingoni A, Soriani A, Ricci B, Molfetta R et al. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC Cancer 2015; 15:17.
37. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134:657-67.
38. Kamran N, Takai Y, Miyoshi J, Biswas SK, Wong JS, Gasser S. Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PLoS ONE 2013; 8:e54406.
39. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 2005; 6:181-8.
40. Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR et al. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J Gen Virol 2010; 91:2034-9.
41. Pappworth IY, Wang EC, Rowe M. The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol 2007; 81:474-82.
42. Bolduan S, Reif T, Schindler M, Schubert U. HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain. Virology 2014; 464:375-84.
43. Matusali G, Potesta M, Santoni A, Cerboni C, Doria M. The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J Virol 2012; 86:4496-504.
44. Lozano E, Joller N, Cao Y, Kuchroo VK, Hafler DA. The CD226/CD155 interaction regulates the proinflammatory (Th1/Th17)/anti-inflammatory (Th2) balance in humans. J Immunol 2013; 191:3673-80.
45. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-42.
46. Ramsbottom KM, Hawkins ED, Shimoni R, McGrath M, Chan CJ, Russell SM, Smyth MJ, Oliaro J. Cutting edge: DNAX accessory molecule 1-deficient CD8+ T cells display immunological synapse defects that impair antitumor immunity. J Immunol 2014; 192:553-7.
47. Balsamo M, Zambello R, Teramo A, Pedrazzi M, Sparatore B, Scordamaglia F et al. Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30. Exp Hematol 2009; 37:1167-75.
48. Ardolino M, Zingoni A, Cerboni C, Cecere F, Soriani A, Iannitto ML, Santoni A. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood 2011; 117:4778-86.
49. Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013; 34:182-91.
50. Upshaw JL, Leibson PJ. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol 2006; 18:167-75.
51. Ralston KJ, Hird SL, Zhang X, Scott JL, Jin B, Thorne RF et al. The LFA-1-associated molecule PTA-1 (CD226) on T cells forms a dynamic molecular complex with protein 4.1G and human discs large. J Biol Chem 2004; 279:33816-28.
52. Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, Miyamoto A et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med 2003; 198:1829-39.
53. Kim HS, Long EO. Complementary phosphorylation sites in the adaptor protein SLP-76 promote synergistic activation of natural killer cells. Sci Signal 2012; 5:ra49.
54. Kim HS, Das A, Gross CC, Bryceson YT, Long EO. Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity 2010; 32:175-86.
55. Tahara-Hanaoka S, Shibuya K, Kai H, Miyamoto A, Morikawa Y, Ohkochi N, Honda S, Shibuya A. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 2006; 107:1491-6.
56. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010; 184:902-11.
57. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008; 205:2959-64.
58. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008; 45:3917-25.
59. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N et al. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 2011; 17:2628-37.
60. Morgado S, Sanchez-Correa B, Casado JG, Duran E, Gayoso I, Labella F, Solana R, Tarazona R. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun 2011; 3:365-73.
61. Pende D, Bottino C, Castriconi R, Cantoni C, Marcenaro S, Rivera P et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 2005; 42:463-9.
62. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Investig 2009; 119:1251-63.
63. Textor S, Durst M, Jansen L, Accardi R, Tommasino M, Trunk MJ et al. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008; 123:2343-53.
64. Hou S, Zheng X, Wei H, Tian Z, Sun R. Recombinant soluble CD226 protein directly inhibits cancer cell proliferation in vitro. Int Immunopharmacol 2014; 19:119-26.
65. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105:2066-73.
66. Zhang Z, Su T, He L, Wang H, Ji G, Liu X, Zhang Y, Dong G. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma. Tohoku J Exp Med 2012; 226:59-68.
67. Carlsten M, Bjorkstrom NK, Norell H, Bryceson Y, van Hall T, Baumann BC et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007; 67:1317-25.
68. Pfeiffer M, Seitz G, Ruck P, Mueller C, Steinle A, Lang P et al. CD155 is involved in NK-cell mediated lysis of human hepatoblastoma in vitro. Front Biosci (Elite Ed) 2011; 3:1456-66.
69. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71:5412-22.
70. Martinovic KMM, Babovic NL, Dzodic RR, Jurisic VB, Tanic NT, Konjevic GM. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. Melanoma Res 2014; 24:295-304.
71. Xu Z, Zhang T, Zhuang R, Zhang Y, Jia W, Song C et al. Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients. BMC Immunol 2009; 10:34.
72. Qu P, Huang X, Zhou X, Lu Z, Liu F, Shi Z et al. Loss of CD155 expression predicts poor prognosis in hepatocellular carcinoma. Histopathology 2015; 66:706-14.
73. Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 2004; 4:73.
74. Nagumo Y, Iguchi-Manaka A, Yamashita-Kanemaru Y, Abe F, Bernhardt G, Shibuya A, Shibuya K. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice. PLoS ONE 2014; 9:e112415.
75. Leung W. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res 2014; 20:3390-400.
76. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527.
77. Qian X, Wang X, Jin H. Cell transfer therapy for cancer: past, present, and future. J Immunol Res 2014; 2014:525913.
78. Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology 2014; 3:e28147.
79. Wu MR, Zhang T, Alcon A, Sentman CL. DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. Cancer Immunol Immunother 2015; 64:409-18.
80. Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014; 28:917-27.
81. Morisaki T, Onishi H, Katano M. Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res 2012; 32:2241-7.
82. Welch MJ, Teijaro JR, Lewicki HA, Colonna M, Oldstone MBA. CD8 T cell defect of TNF-α, and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection. Virology 2012; 429:163-70.
83. Magri G, Muntasell A, Romo N, Saez-Borderias A, Pende D, Geraghty DE et al. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 2011; 117:848-56.
84. Stegmann KA, Bjorkstrom NK, Ciesek S, Lunemann S, Jaroszewicz J, Wiegand J et al. Interferon-α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis 2012; 205:1351-62.
85. + T-cell exhaustion in chronic HIV-1 infection. Eur J Immunol 2010; 40:949-54.
86. Reymond N, Imbert AM, Devilard E, Fabre S, Chabannon C, Xerri L et al. DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med 2004; 199:1331-41.
87. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 2005; 106:2252-8.
88. Chiche L, Forel JM, Thomas G, Farnarier C, Vely F, Blery M, Papazian L, Vivier E. The role of natural killer cells in sepsis. J Biomed Biotechnol 2011; 2011:986491.
89. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285:412-5.
90. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-100.
91. + T cells responsible for the exacerbation of acute graft-versus-host disease. Proc Natl Acad Sci USA 2011; 108:E34-E.
92. Koyama M, Kuns RD, Olver SD, Lineburg KE, Lor M, Teal BE et al. Promoting regulation via the inhibition of DNAM-1 after transplantation. Blood 2013; 121:3511-20.
93. Du Y, Tian L, Shen LX, Wang F, Yu LK, Song Y, Zhu JF, Du R. Association of the CD226 single nucleotide polymorphism with systemic lupus erythematosus in the Chinese Han population. Tissue Antigens 2011; 77:65-7.
94. Avouac J, Elhai M, Tomcik M, Ruiz B, Friese M, Piedavent M et al. Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 2013; 72:1089-98.
95. Elhai M, Chiocchia G, Marchiol C, Lager F, Renault G, Colonna M et al. Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models. J Inflamm 2015; 12:9.
96. Mattana TC, Santos AS, Fukui RT, Mainardi-Novo DT, Costa VS, Santos RF, Matioli SR, da Silva ME. CD226 rs763361 is associated with the susceptibility to type 1 diabetes and greater frequency of GAD65 autoantibody in a Brazilian cohort. Mediators Inflamm 2014; 2014:694948.
97. Nielsen N, Pascal V, Fasth AE, Sundstrom Y, Galsgaard ED, Ahern D et al. Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. Immunology 2014; 142:581-93.
98. Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther 2013; 15:216.
99. Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006; 20:896-905.